Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report-Reference-Cited by-同舟云学术

Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report

Published:2020-11 Issue:11 Volume:48 Page:030006052096435
ISSN:0300-0605
Container-title:Journal of International Medical Research
language:en
Short-container-title:J Int Med Res

Author:

Chen Jingxian¹,Cheng Chien-shan²³,Chen Jie⁴,Lv Lingling¹,Shen Xiaoheng¹,Zheng Lan¹^ORCID

Affiliation:

1. Department of Traditional Chinese Medicine, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, China

2. Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

3. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

4. Department of Orthopedics, Shanghai Institute of Traumatology and Orthopedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Abstract

The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular endothelial growth factor A amplification and the TP53 R209Kfs mutation. Treatment with the multi-targeted protein kinase inhibitor sorafenib controlled the patient’s symptoms and improved his quality of life.

Funder

Shanghai Science and Technology Committee Scientific Research

Famous Chinese Medicine Academic Research Studio of Shanghai city

Publisher

SAGE Publications

Subject

Biochemistry (medical),Cell Biology,Biochemistry,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/0300060520964355

Reference17 articles.

1. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

2. The discovery and development of sorafenib for the treatment of thyroid cancer

3. Cancer of Unknown Primary Site

4. Cancer of unknown primary patients with midline nodal distribution: Midway between poor and favourable prognosis?

5. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adenocarcinoma of unknown primary with TP53 gene polymorphism: a rare case report with literature review;Future Journal of Pharmaceutical Sciences;2024-07-18

2. Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement;Frontiers in Pharmacology;2023-01-23

3. Sorafenib;Reactions Weekly;2021-01